The Endocrine Society and Keystone Symposia, a nonprofit host of conferences and symposia on a range of life science and biomedical topics, will jointly host a series of three conferences to advance endocrine research. The three conferences will focus on diabetes, oncology, and cardiovascular disease — hormone-related conditions that have a major impact on public...
When a presentation at ENDO 2024 highlighted a male contraceptive gel that suppresses sperm production faster than other hormone-focused methods of male birth control, the Boston Convention Center was abuzz. Containing segesterone acetate and testosterone and applied to both shoulders, this groundbreaking new birth control could prove revolutionary. When the results from an ongoing multicenter...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two phase III Trials in MASH for Survodutide On October 8, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a...
Shumei Meng, MD, PhD, from the Baylor University Medical Center and the Texas A&M School of Medicine, discusses a remarkable case study from JCEM Case Reports detailing how endocrinologists may have discovered a new syndromic association that may have saved a pregnant patient’s life. Sometimes in medicine, everything aligns, and patients with unusual presentations who...
Endocrine Society Endorses Right to IVF Act In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families...
By John Newell-Price, MD, PhD, President, Endocrine Society I’ve been a proud member of the Endocrine Society for more than two decades. Each year as October comes around, I renew my membership, and I really encourage you to do so too. If you haven’t already done so, now is the perfect time to renew for...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Priority Review Granted for HER2-low or HER2-ultralow Metastatic Breast Cancer Treatment On October 1, AstraZeneca and Daiichi Sankyo announced that its supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the...
As Artificial Intelligence (AI) finds its way into all aspects of daily life, soon it could be an important component of scientific research, patient care, and the ins and outs of clinical practice. On November 8 and 9, the Endocrine Society will host the AI in Healthcare Virtual Summit that will cover a variety of...
Shumei Meng, MD, PhD, from the Baylor University Medical Center and the Texas A&M School of Medicine, discusses a remarkable case study from JCEM Case Reports detailing how endocrinologists may have discovered a new syndromic association that may have saved a pregnant patient’s life. Sometimes in medicine, everything aligns, and patients with unusual presentations who...
